본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

Clinical chemistry 20건

  1. [해외논문]   Clinical Chemistry Views and Policy on Preprints   SCI SCIE

    Rifai, Nader (Boston Children's Hospital, Boston, MA) , Annesley, Thomas M. (University of Michigan, Ann Arbor, MI) , Boyd, James C. (Department of Pathology, University of Virginia Health System, Charlottesville, VA.)
    Clinical chemistry v.64 no.7 ,pp. 989 - 990 , 2018 , 0009-9147 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [해외논문]   Development of Immunochromatographic Assays for the Selective Detection of Zika Virus or Dengue Virus Serotypes in Serum   SCI SCIE

    Hage, David S. (Department of Chemistry, University of Nebraska, Lincoln, NE.)
    Clinical chemistry v.64 no.7 ,pp. 991 - 993 , 2018 , 0009-9147 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [해외논문]   What's New in Laboratory Test Utilization Management?   SCI SCIE

    Baird, Geoffrey S. (Associate Professor and Interim Chair, Department of Laboratory Medicine, University of Washington, Seattle, WA) , Jackson, Brian R. (Associate Professor of Pathology (Clinical), Department of Pathology, University of Utah, and Chief Medical Information Officer, ARUP Laboratories, Salt Lake City, UT) , Dickerson, Jane (Director of Chemistry and Reference Laboratory Services, Seattle Children's Hospital, Seattle, WA) , Sikaris, Ken (Director, Clinical Support Systems, Sonic Healthcare, Melbourne University, Melbourne, Australia) , Croal, Bernard (Clinical Director, Laboratory Medicine, NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, Scotland) , Laposata, Michael (Chairman, Department of Pathology, University of Texas Medical Branch, Galveston, TX.)
    Clinical chemistry v.64 no.7 ,pp. 994 - 1000 , 2018 , 0009-9147 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [해외논문]   Fill in the Gaps: An Unresponsive 55-Year-Old Man   SCI SCIE

    Gau, Nicholas (Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO. ) , Scott, Mitchell G. (Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.)
    Clinical chemistry v.64 no.7 ,pp. 1001 - 1004 , 2018 , 0009-9147 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [해외논문]   Commentary   SCI SCIE

    Nichols, James H. (Vanderbilt University Medical Center, Nashville, TN.)
    Clinical chemistry v.64 no.7 ,pp. 1004 - 1005 , 2018 , 0009-9147 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [해외논문]   Commentary   SCI SCIE

    Sanchez, Leon D. (Harvard Medical School, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA.)
    Clinical chemistry v.64 no.7 ,pp. 1005 - 1005 , 2018 , 0009-9147 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [해외논문]   Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM   SCI SCIE

    Langlois, Michel R. (Department of Laboratory Medicine, AZ St-Jan, Brugge, and University of Ghent, Belgium) , Chapman, M. John (National Institute for Health and Medical Research (INSERM), and Endocrinology-Metabolism Service, Pitié-Salpetriere University Hospital, Paris, France) , Cobbaert, Christa (Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands) , Mora, Samia (Divisions of Preventive and Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA) , Remaley, Alan T. (Lipoprotein Metabolism Section, Cardiovascular-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD) , Ros, Emilio (Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clínic, Barcelona and Ciber Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain) , Watts, Gerald F. (Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital,) , Boré , n, Jan , Baum, Hannsjö , rg , Bruckert, Eric , Catapano, Alberico , Descamps, Olivier S. , von Eckardstein, Arnold , Kamstrup, Pia R. , Kolovou, Genovefa , Kronenberg, Florian , Langsted, Anne , Pulkki, Kari , Rifai, Nader , Sypniewska, Grazyna , Wiklund, Olov , Nordestgaard, Børge G.
    Clinical chemistry v.64 no.7 ,pp. 1006 - 1033 , 2018 , 0009-9147 ,

    초록

    BACKGROUND: The European Atherosclerosis Society–European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management. CONTENT: We critically examined LDL cholesterol, non-HDL cholesterol, apolipoprotein B (apoB), and LDL particle number assays based on key criteria for medical application of biomarkers. ( a ) Analytical performance: Discordant LDL cholesterol quantification occurs when LDL cholesterol is measured or calculated with different assays, especially in patients with hypertriglyceridemia >175 mg/dL (2 mmol/L) and low LDL cholesterol concentrations <70 mg/dL (1.8 mmol/L). Increased lipoprotein(a) should be excluded in patients not achieving LDL cholesterol goals with treatment. Non-HDL cholesterol includes the atherogenic risk component of remnant cholesterol and can be calculated in a standard nonfasting lipid panel without additional expense. ApoB more accurately reflects LDL particle number. ( b ) Clinical performance: LDL cholesterol, non-HDL cholesterol, and apoB are comparable predictors of cardiovascular events in prospective population studies and clinical trials; however, discordance analysis of the markers improves risk prediction by adding remnant cholesterol (included in non-HDL cholesterol) and LDL particle number (with apoB) risk components to LDL cholesterol testing. ( c ) Clinical and cost-effectiveness: There is no consistent evidence yet that non-HDL cholesterol-, apoB-, or LDL particle-targeted treatment reduces the number of cardiovascular events and healthcare-related costs than treatment targeted to LDL cholesterol. SUMMARY: Follow-up of pre- and on-treatment (measured or calculated) LDL cholesterol concentration in a patient should ideally be performed with the same documented test method. Non-HDL cholesterol (or apoB) should be the secondary treatment target in patients with mild to moderate hypertriglyceridemia, in whom LDL cholesterol measurement or calculation is less accurate and often less predictive of cardiovascular risk. Laboratories should report non-HDL cholesterol in all standard lipid panels.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [해외논문]   Sex-Specific Versus Overall Clinical Decision Limits for Cardiac Troponin I and T for the Diagnosis of Acute Myocardial Infarction: A Systematic Review   SCI SCIE

    Kimenai, Dorien M. (Department of Central Diagnostic Laboratory, Clinical Chemistry, Maastricht University Medical Center, Maastricht, the Netherlands) , Janssen, Emma B.N.J. (Department of Central Diagnostic Laboratory, Clinical Chemistry, Maastricht University Medical Center, Maastricht, the Netherlands) , Eggers, Kai M. (Department of Medical Sciences, Uppsala University, Uppsala, Sweden) , Lindahl, Bertil (Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden) , den Ruijter, Hester M. (Laboratory of Experimental Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands) , Bekers, Otto (Department of Central Diagnostic Laboratory, Clinical Chemistry, Maastricht University Medical Center, Maastricht, the Netherlands) , Appelman, Yolande (Department of Cardiology, VU University Medical Center, Amsterdam, the Netherlands. ) , Meex, Steven J.R. (Department of Central Diagnostic Laboratory, Clinical Chemistry, Maastricht University Medical Center, Maastricht, the Netherlands;)
    Clinical chemistry v.64 no.7 ,pp. 1034 - 1043 , 2018 , 0009-9147 ,

    초록

    BACKGROUND: The overall clinical decision limits of high-sensitivity cardiac troponin I (hs-cTnI; 26 ng/L) and T (hs-cTnT; 14 ng/L) may contribute to underdiagnosis of acute myocardial infarction in women. We performed a systematic review to investigate sex-specific and overall 99th percentiles of hs-cTnI and hs-cTnT derived from healthy reference populations. CONTENT: We searched in PubMed and EMBASE for original studies, and by screening reference lists. Reference populations designed to establish 99th percentiles of hs-cTnI (Abbott) and/or hs-cTnT (Roche), published between January 2009 and October 2017, were included. Sex-specific and overall 99th percentile values of hs-cTnI and hs-cTnT were compared with overall clinical decision ranges (hs-cTnI, 23–30 ng/L; hs-cTnT, 13–25 ng/L). Twenty-eight studies were included in the systematic review. Of 16 hs-cTnI and 18 hs-cTnT studies, 14 (87.5%) and 11 (61.1%) studies reported lower female-specific hs-cTn cutoffs than overall clinical decision ranges, respectively. Conversely, male-specific thresholds of both hs-cTnI and hs-cTnT were in line with currently used overall thresholds, particularly hs-cTnT (90% concordance). The variation of estimated overall 99th percentiles was much higher for hs-cTnI than hs-cTnT (29.4% vs 80.0% of hs-cTnI and hs-cTnT studies reported values within the current overall clinical decision range, respectively). SUMMARY: Our data show substantially lower female-specific upper reference limits of hs-cTnI and hs-cTnT than overall clinical decision limits of 26 ng/L and 14 ng/L, respectively. The statistical approach strongly affects the hs-cTnI threshold. Downward adjustment of hs-cTn thresholds in women may be warranted to reduce underdiagnosis of acute myocardial infarction in women.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [해외논문]   Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study   SCI SCIE

    Than, Martin P. (Christchurch Hospital, Christchurch, New Zealand) , Aldous, Sally J. (Christchurch Hospital, Christchurch, New Zealand) , Troughton, Richard W. (Christchurch Hospital, Christchurch, New Zealand) , Pemberton, Christopher J. (Christchurch Heart Institute, University of Otago Christchurch, Christchurch, New Zealand) , Richards, A. Mark (Christchurch Heart Institute, University of Otago Christchurch, Christchurch, New Zealand) , Frampton, Christopher M.A. (Christchurch Heart Institute, University of Otago Christchurch, Christchurch, New Zealand) , Florkowski, Christopher M. (Christchurch Hospital, Christchurch, New Zealand) , George, Peter M. (Christchurch Hospital, Christchurch, New Zealand) , Bailey, Samantha (Christchurch Hospital, Christchurch, New Zealand) , Young, Joanna M. (Christchurch Hospital, Christchurch, New Zealand) , Cullen, Louise (Royal Brisbane and Women's Hospital, Herston, Australia) , Greenslade, Jaimi H. (Royal Brisbane and Women's Hospital, Herston, Australia) , Parsonage, William A. (Royal Brisbane and Women's Hospital, Herston, Australia) , Everett, Brendan M. (Divisions of Cardiovascular and Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA) , Peacock, W. Frank (Baylor College of Medicine, Houston, TX) , Jaffe, Allan S. (Mayo Clinic,) , Pickering, John W.
    Clinical chemistry v.64 no.7 ,pp. 1044 - 1053 , 2018 , 0009-9147 ,

    초록

    BACKGROUND: Increased cardiac troponin I or T detected by high-sensitivity assays (hs-cTnI or hs-cTnT) confers an increased risk of adverse prognosis. We determined whether patients presenting with putatively normal, detectable cTn concentrations [> limit of detection and < upper reference limit (URL)] have increased risk of major adverse cardiovascular events (MACE) or all-cause mortality. METHODS: A prospective 5-year follow-up of patients recruited in the emergency department with possible acute coronary syndrome (ACS) and cTn concentrations measured with hs-cTnI (Abbott) and hs-cTnT (Roche) assays. Cox regression models were generated with adjustment for covariates in those without MACE on presentation. Hazard ratios (HRs) for hs-cTn were calculated relative to the HRs at the median concentration. RESULTS: Of 1113 patients, 836 were without presentation MACE. Of these, 138 incurred a MACE and 169 died during a median 5.8-year follow-up. HRs for MACE at the URLs were 2.3 (95% CI, 1.7–3.2) for hs-cTnI and 1.8 (95% CI, 1.3–2.4) for hs-cTnT. Corresponding HRs for mortality were 1.7 (95% CI, 1.2–2.2) for hs-cTnI and 2.3 (95 % CI, 1.7–3.1) for hs-cTnT. The HR for MACE increased with increasing hs-cTn concentration similarly for both assays, but the HR for mortality increased at approximately twice the rate for hs-cTnT than hs-cTnI. Patients with hs-cTnI ≥10 ng/L or hs-cTnT ≥16 ng/L had the same percentage of MACE at 5-year follow-up (33%) as patients with presentation MACE. CONCLUSIONS: Many patients with ACS ruled out and putatively normal but detectable hs-cTnI concentrations are at similar long-term risk as those with MACE. hs-cTnT concentrations are more strongly associated with 5-year mortality than hs-cTnI.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  10. [해외논문]   RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients   SCI SCIE

    Keup, Corinna (Department of Gynecology and Obstetrics, University Hospital of Essen, Germany) , Mach, Pawel (Department of Gynecology and Obstetrics, University Hospital of Essen, Germany) , Aktas, Bahriye (Department of Gynecology and Obstetrics, University Hospital of Essen, Germany) , Tewes, Mitra (Department of Internal Medicine (Cancer Research), University Hospital of Essen, Germany) , Kolberg, Hans-Christian (Clinic for Gynecology and Obstetrics, Marienhospital Bottrop, Germany) , Hauch, Siegfried (QIAGEN GmbH, Hilden, Germany. ) , Sprenger-Haussels, Markus (QIAGEN GmbH, Hilden, Germany. ) , Kimmig, Rainer (Department of Gynecology and Obstetrics, University Hospital of Essen, Germany) , Kasimir-Bauer, Sabine (Department of Gynecology and Obstetrics, University Hospital of Essen, Germany;)
    Clinical chemistry v.64 no.7 ,pp. 1054 - 1062 , 2018 , 0009-9147 ,

    초록

    BACKGROUND: Liquid biopsies are discussed to provide surrogate markers for therapy stratification and monitoring. We compared messenger RNA (mRNA) profiles of circulating tumor cells (CTCs) and extracellular vesicles (EVs) in patients with metastatic breast cancer (MBC) to estimate their utility in therapy management. METHODS: Blood was collected from 35 hormone receptor-positive/HER2-negative patients with MBC at the time of disease progression and at 2 consecutive staging time points. CTCs were isolated from 5 mL of blood by positive immunomagnetic selection, and EVs from 4 mL of plasma by a membrane affinity-based procedure. mRNA was reverse transcribed, preamplified, and analyzed for 18 genes by multimarker quantitative polymerase chain reaction (qPCR) assays. RNA profiles were normalized to healthy donor controls (n = 20), and results were correlated with therapy outcome. RESULTS: There were great differences in mRNA profiles of EVs and CTCs, with only 5% (21/403) of positive signals identical in both fractions. Transcripts involved in the PI3K signaling pathway were frequently overexpressed in CTCs, and AURKA , PARP1 , and SRC signals appeared more often in EVs. Of all patients, 40% and 34% showed ERBB2 and ERBB3 signals, respectively, in CTCs, which was significantly associated with disease progression ( P = 0.007). Whereas MTOR signals in CTCs significantly correlated with response ( P = 0.046), signals in EVs indicated therapy failure ( P = 0.011). The presence of AURKA signals in EVs seemed to be a marker for the indication of unsuccessful treatment of bone metastasis. CONCLUSIONS: These results emphasize the potential of CTCs and EVs for therapy monitoring and the need for critical evaluation of the implementation of any liquid biopsy in clinical practice.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지